CYRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Cryoport, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$16.98+0.14 (+0.83%)
Close on Oct 19, 2026
- Market cap
- $856.52M
- P/E (TTM)
- –
- Dividend yield
- –
Cryoport, Inc. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aggregate of reportable segment | $50.22M | – | $44.18M | $44.55M | $46.02M | $41.44M | $40.56M | $38.58M | $40.08M | $37.55M | – | – | 102.6% | +9.1% |
| Life Sciences Services | $28.22M | $27.44M | $26.50M | $25.50M | $25.82M | $23.21M | $22.59M | $21.30M | – | – | – | – | 57.6% | +9.3% |
| Life Sciences Products | $20.76M | $20.36M | $18.95M | $18.74M | $19.64M | $17.83M | $18.86M | $17.02M | – | – | – | – | 42.4% | +5.7% |
| Life Science Supply Chain Solutions | – | – | – | – | $25.82M | $23.21M | – | – | $21.57M | $19.87M | – | – | – | – |
| Life Science Systems | – | – | – | – | $19.64M | $17.83M | – | – | $18.14M | $17.42M | – | – | – | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Service | $27.97M | $26.90M | $25.01M | $24.26M | $24.37M | $22.87M | $21.48M | $20.93M | $20.15M | $19.49M | $37.03M | $36.02M | 57.1% | +14.8% |
| BioLogistics Solutions | $22.36M | $21.67M | $20.31M | $19.43M | $19.87M | $18.53M | $17.48M | $16.96M | $16.63M | $15.96M | $33.41M | $32.49M | 45.7% | +12.5% |
| Product | $21.00M | $20.90M | $20.45M | $19.98M | $21.09M | $18.18M | $19.98M | $17.39M | $19.56M | $17.81M | $20.24M | $20.14M | 42.9% | -0.4% |
| BioStorage/BioServices | $5.61M | $5.23M | $4.70M | $4.83M | $4.50M | $4.33M | $4.00M | $3.98M | $3.52M | $3.53M | $3.62M | $3.54M | 11.5% | +24.8% |
| Biopharmaceutical | – | – | – | – | – | – | – | – | – | – | $47.95M | $46.98M | – | – |
| Animal Health | – | – | – | – | – | – | – | – | – | – | $6.76M | $6.88M | – | – |
| Reproductive Medicine | – | – | – | – | – | – | – | – | – | – | $2.55M | $2.29M | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Americas | $36.89M | $34.96M | $32.69M | $33.14M | $33.24M | $32.20M | $29.60M | $27.84M | $29.42M | $26.69M | $21.54M | $31.57M | 75.3% | +11.0% |
| Europe, the Middle East, and Africa (EMEA) | $8.03M | $8.95M | $7.09M | $6.63M | $5.83M | $5.58M | $6.89M | $6.20M | $6.53M | $7.40M | $13.38M | $14.24M | 16.4% | +37.7% |
| Asia Pacific (APAC) | $4.05M | $3.89M | $5.68M | $4.46M | $6.38M | $3.27M | $4.97M | $4.28M | $3.76M | $3.20M | $13.02M | $10.35M | 8.3% | -36.6% |
From the segment and revenue-disaggregation notes of Cryoport's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.